Welcome to our dedicated page for CARLSMED SEC filings (Ticker: CARL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Carlsmed, Inc. filings document the regulatory record of a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions. Recent 8-K filings report results of operations and financial condition, including furnished earnings releases tied to the company’s aprevo® platform, product activity and revenue outlook.
The company’s SEC materials also cover emerging growth company status, annual meeting and proxy governance matters, and capital-structure disclosures. Material-event filings include amendments to loan and security arrangements, credit facility terms, warrant-related disclosures and other financing matters relevant to Carlsmed’s public-company reporting.
Carlsmed, Inc. amended its loan agreement with Customers Bank, adding a credit facility consisting of a Term Loan of up to $50.0 million and a $10.0 million non‑formula revolver, with total advances capped at $50.0 million. Of the Term Loan, $17.5 million is contingent on revenue milestones. The interest rate is the greater of WSJ Prime + 0.25% or 5.25%, which was 7.50% as of September 30, 2025.
The Term Loan matures on October 15, 2030 with interest‑only through October 15, 2027, extendable to October 15, 2028 upon milestone achievement. The revolver matures on October 15, 2028. The company must keep at least $20.0 million in an operating account at Customers Bank and meet minimum revenue thresholds if deposits are less than 100% of outstanding debt.
Carlsmed also reduced warrant overhang tied to future draws: the Series B warrant decreased from 58,420 to 52,776 shares, and the Series C from 20,375 to 10,188, cancelling contingent rights to 15,831 shares in total.
Carlsmed, Inc. reported items in its Quarterly Report highlighting its recent IPO proceeds, debt amendments, warrants and liquidity arrangements, and ongoing risks tied to commercialization of the aprevo Technology Platform. The IPO generated approximately $93.5 million of gross proceeds (after underwriting discounts and commissions and before offering expenses) with the underwriters' 30-day option for an additional 1,005,000 shares not exercised. The condensed financial statements do not reflect the shares or proceeds from the IPO for the three and six months ended June 30, 2025.
The company disclosed amended credit facilities that expanded available principal from $12.5 million to $18.8 million and later to up to $27.5 million with draw tranches; as of June 30, 2025 the company could draw $7.5 million immediately and an additional $4.4 million contingent on revenue milestones not yet met. Interest terms included a coupon of 7.75% as of June 30, 2025 and extended maturities to October 31, 2029 with interest-only periods tied to milestone achievement. Other noted items include provision for credit losses of $0.3 million for the three and six months ended June 30, 2025, stock-based awards covering 4,055,427 shares, outstanding warrants and preferred conversion features, and the company remaining in an accumulated deficit position which affected deemed dividends recorded to APIC.
Carlsmed, Inc. filed a current report to disclose that it has released its financial results for the quarter ended June 30, 2025. On August 28, 2025, the company issued a press release with these quarterly results, which is included as Exhibit 99.1 to the report.
The press release describing the quarter’s results is being furnished rather than filed, meaning it is not automatically subject to certain liability provisions and is not automatically incorporated into other securities filings unless specifically referenced. The company’s common stock, with a par value of $0.00001 per share, trades on The Nasdaq Stock Market LLC under the symbol CARL.